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Abstract
Interferons (IFNs) play a crucial role in the antiviral immune response. Whereas the C proteins of wild-type human
parainfluenza virus type 1 (WT HPIV1) inhibit both IFN-b induction and signaling, a HPIV1 mutant encoding a single amino
acid substitution (F170S) in the C proteins is unable to block either host response. Here, signaling downstream of the type 1
IFN receptor was examined in Vero cells to define at what stage WT HPIV1 can block, and F170S HPIV1 fails to block, IFN
signaling. WT HPIV1 inhibited phosphorylation of both Stat1 and Stat2, and this inhibition was only slightly reduced for
F170S HPIV1. Degradation of Stat1 or Stat2 was not observed. The HPIV1 C proteins were found to accumulate in the
perinuclear space, often forming large granules, and co-localized with Stat1 and the cation-independent mannose 6-
phosphate receptor (M6PR) that is a marker for late endosomes. Upon stimulation with IFN-b, both the WT and F170S C
proteins remained in the perinuclear space, but only the WT C proteins prevented Stat1 translocation to the nucleus. In
addition, WT HPIV1 C proteins, but not F170S C proteins, co-immunoprecipitated both phosphorylated and
unphosphorylated Stat1. Our findings suggest that the WT HPIV1 C proteins form a stable complex with Stat1 in
perinuclear granules that co-localize with M6PR, and that this direct interaction between the WT HPIV1 C proteins and Stat1
is the basis for the ability of HPIV1 to inhibit IFN signaling. The F170S mutation in HPIV1 C did not prevent perinuclear co-
localization with Stat1, but apparently weakened this interaction such that, upon IFN stimulation, Stat1 was translocated to
the nucleus to induce an antiviral response.
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Introduction
HPIV1 is the most common cause of croup and is an important
respiratory pathogen in young children, the elderly, and the
immunocompromised [1,2,3]. Although most of the burden of
disease in children is treated on an outpatient basis, HPIV
serotypes 1, 2, and 3 account for 7% of all hospitalizations for
fever and/or acute respiratory illnesses in children under 5 years of
age [4]. HPIV infections do not induce complete protection
against re-infection, and most of us likely have experienced
multiple respiratory illnesses due to HPIVs. However, while host
immunity is inefficient in preventing re-infection, it does reduce
virus replication and disease during re-infections. The ability of
HPIVs to re-infect symptomatically without significant antigenic
change is due in part to their tropism to the superficial respiratory
epithelium, where the efficiency of immune protection is reduced.
HPIV1 is a Respirovirus in the subfamily Paramyxovirinae,
family Paramyxoviridae, order Mononegavirales. Its single strand
negative sense RNA genome, 15.6 kb in length, contains 6 genes
(39 – N-P/C-M-F-HN-L – 59) that encode the nucleoprotein (N),
phosphoprotein (P), C proteins (C), matrix protein (M), fusion
protein (F), hemagglutinin-neuraminidase protein (HN), and the
large polymerase protein (L). Each gene encodes a single protein
with the exception of the P/C gene, which encodes the P protein
in one open reading frame and a nested set of four carboxy-
coterminal C proteins (C9, C, Y1, and Y2, amino acid lengths of
219, 204, 181, and 175, respectively) expressed from individual
start sites in a second open reading frame.
Sendai virus (SeV), the most-extensively characterized PIV, is
the murine homologue of HPIV1, with considerable sequence
relatedness. However, the P/C gene organization of SeV differs
from that of HPIV1 in that SeV engages in RNA editing to
express, in addition to the C proteins, a second accessory protein
called V protein that also inhibits the innate antiviral response as
well as having other roles in the replicative cycle [5]. In contrast,
HPIV1 does not edit and does not express a V protein. In
addition, some of the immune evasion activities of SeV and
HPIV1 are species-specific [6,7], and the two viruses clearly differ
in their host range: The lethal dose 50% of some SeV strains is less
than 100 infectious units for mice [8,9] whereas adult humans
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7 infectious units of SeV do not develop any
respiratory illness [10]. In contrast, even high doses of HPIV1 do
not cause disease in mice, whereas HPIV1 causes respiratory
illness in more than 50% of healthy adults inoculated with less
than 100 infectious units of virus [11].
The lack of a V protein sets HPIV1 apart not only from SeV but
also from most of the other viruses of the Paramyxovirinae
subfamily. With the exception of HPIV1 and HPIV3 – the latter of
which either does not express a V protein or does so inefficiently
[12,13] – all members of the Paramyxovirinae subfamily appear to
express a V protein. The C-terminal domain of the V protein has a
cysteine-rich motif that is highly conserved in Paramyxovirinae
[14]. While most members of Paramyxovirinae express a V
protein, C proteins are expressed only by members of genus
Respirovirus (e.g., HPIV1 and HPIV3), Morbillivirus (e.g., measles
virus), and Henipavirus (i.e., Nipah and Hendra viruses). In
contrast to the V protein, the C proteins do not have any obvious
motifs that are conserved across those viruses that express C.
The phenylalanine 170 to serine (F170S) substitution in the C
proteins of SeV was initially discovered because it rendered the
mutant virus avirulent in mice [15]. Later it was shown that the
SeV C proteins were sufficient to block IFN-b signaling [16,17]
whereas both the C and V proteins have been shown to participate
in the inhibition of type 1 IFN induction [7,18]. The SeV C
proteins have also been shown to play roles in the regulation of
viral RNA synthesis [19], in virus assembly [20], selective
packaging of negative sense RNA genomes into the virion [21],
virus budding [22] and inhibition of apoptosis [23]. Some of these
activities remain controversial. For example, the report that virion
budding depends on interaction between the C protein and a
cellular protein called Alix was not confirmed [24]. Also, as noted
below, the mechanism(s) by which the SeV C proteins block
signaling from the IFN receptor remains unclear.
The HPIV1 C proteins are much less well characterized but
have been shown to inhibit apoptosis and IFN-b signaling
[6,25,26,27]. We previously transferred the F170S mutation into
HPIV1 by reverse genetics, which resulted in a virus that is highly
attenuated in non-human primates [15,25,26,28,29]. Studies with
this virus showed that the HPIV1 C proteins regulate and restrain
viral RNA synthesis to prevent the formation of dsRNA, thereby
indirectly preventing IFN-b induction and activation of protein
kinase R [30]. In addition, mutation or deletion of C is associated
with changes in the expression of more than 2000 cellular genes
compared to WT HPIV1 [27]. Since IFN secretion leads to the
establishment of an antiviral state in both infected and non-
infected cells, both virus spread and virus replication are restricted
[31]. The F170S mutation in HPIV1 is one of the major
attenuating mutations in a live HPIV1 vaccine candidate presently
in clinical trials (clinicaltrials.gov NCT00641017) [32].
Type 1 IFNs (notably IFN- a and b) and Type 2 IFN (IFN-c)
signal through different receptors, but both types of IFN employ
the Jak/Stat signaling pathway [33]. Jak/Stat signaling is initiated
by binding of IFN to its transmembrane receptor, which results in
the reorganization and auto-phosphorylation of receptor subunits
and the binding and phosphorylation of Janus kinases (Jak/Tyk).
The Janus kinases then recruit Signal Transducers and Activators
of Transcription (Stats) to this membrane-associated complex and
phosphorylate them. Phosphorylated Stats then form either
Stat1:Stat1 homodimers following IFN-c stimulation, or Stat1:-
Stat2 heterodimers and ISGF3 complexes (Stat1:Stat2:IRF9)
following type 1 IFN stimulation. These dimers or trimers then
translocate to the nucleus where they bind to and activate specific
DNA binding sites [34].
The SeV C proteins strongly inhibit signaling from the IFN-a/b
receptor, but the mechanism(s) remains unclear and appears to
vary with different experimental conditions. One line of
experiments provided evidence of ubiquitination and proteosomal
degradation of Stat1, an effect that involved the two longer C
proteins, C9 and C, but not the shorter Y1 and Y2 forms, and
which could be mimicked by the first 23 amino acids of C
[17,35,36]. Another line of experiments indicated that neither
Stat1 nor Stat2 is degraded, and that the C proteins inhibit
signaling from the IFN receptor by blocking phosphorylation of
both Stat1 and Stat2, with the impaired phosphorylation of Stat2
being the more important effect [37]. The C-terminal 106 residues
of C were sufficient to mediate these latter effects [38], and
residues 151, 153, and 154, in addition to the F170S mutation,
were shown to be important [39]. The inconsistencies in these
results may reflect experimental differences such as the use of
transfected plasmids or stably-expressing cell lines versus infection,
the use of cells from different hosts and in particular from non-host
species, and the use of cells that are competent to express type 1
IFN, which can confound results since Stat1 expression is strongly
up-regulated by type 1 IFN.
HPIV1 has been shown to inhibit translocation of Stat1 and
Stat2 to the nucleus [6], but otherwise the mechanisms by which
the HPIV1 C proteins inhibit IFN signaling were unknown. In the
present study, we used Vero cells (representing African green
monkeys, which are susceptible to HPIV1 infection), which do not
express type 1 IFNs and thus permit evaluation of IFN signaling
without the confounding effects of endogenously-produced IFN, to
examine at what stage in the pathway WT HPIV1 succeeds and
F170S HPIV1 fails to inhibit IFN signaling. In addition, we
studied these effects mostly in the context of viral infection, since
this would provide the most authentic conditions as opposed to
transfected cDNAs or stably expressing cell lines that express
individual proteins outside of the context of the other viral
macromolecules and induced cellular response and with possible
differences in expression levels and subcellular distribution. Given
the lack of a HPIV1 V protein, the activities of the C proteins can
readily be evaluated with fully replication competent viral
mutants. One of the findings of this study was co-localization of
the C proteins and Stat1 with the cellular protein cation-
independent mannose 6-phosphate receptor (M6PR). Mannose
6-phosphate (M6P) is the sorting signal that distinguishes proteins
that are destined to reside in the lysosome from those that are
destined to be transported to the surface or to be secreted [40]. For
proteins destined for the lysosome, N-linked sugars are modified to
contain M6P. These proteins are bound by M6PR in the trans-
Golgi network and are diverted into clathrin-coated vesicles [41].
These vesicles fuse with endosomes carrying serum proteins
ingested at the plasma membrane, creating what are referred to as
late endosomes [42]. A small fraction of M6PR also is localized on
the cell surface, where it binds to M6P-carrying serum proteins
[43], but most of the M6PR is associated with late endosomes, and
M6PR is widely accepted as a late endosome marker.
Results
In contrast to WT HPIV1, F170S HPIV1 is unable to inhibit
IFN-a,- b,o r- c-mediated induction of an antiviral state
We have previously shown that WT HPIV1 is able to inhibit the
IFN-b-mediated induction of an antiviral state in human lung
A549 cells whereas F170S HPIV1 is unable to do so [25]. The
current study sought to better define where in the IFN signaling
pathway this block occurred. We examined the Jak/Stat signaling
pathway in WT HPIV1- and F170S HPIV1-infected Vero cells
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infected with either virus for 48 h, mock-treated or treated with
100 or 1000 IU of IFN-a,- b or -c for 24 h, and superinfected with
GFP-expressing VSV. Two days later, VSV plaques were
enumerated, with inhibition of plaque formation being an
indication of IFN signaling and establishment of an antiviral
state. As expected, IFN-b treatment induced an antiviral state in
mock-infected Vero cells and reduced the number of VSV plaques
by up to 97% in a dose-dependent manner (Figure 1). IFN-a also
reduced the number of VSV plaques in a dose-dependent manner,
as one would expect since IFN-a and IFN-b use the same receptor
and signal through Stat1:Stat2 heterodimers. In contrast, IFN-c
treatment, dependent on a different receptor, reduced the number
of VSV plaques by no more than 53% (Figure 1). This lower level
of inhibition might reflect limited expression of the IFN-c receptor
on Vero cells or a difference in the effectiveness of the cellular
antiviral response to type 1 versus type 2 IFN, which activate
different sets of genes. For all three IFN treatments, prior WT
HPIV1 infection inhibited the IFN-mediated induction of an
antiviral state, thereby permitting VSV to form significantly more
plaques than in mock-infected Vero cells. In contrast, F170S
HPIV1 was unable to inhibit the induction of an IFN-a,- b,o r- c-
mediated antiviral state, so that VSV plaque formation was as
restricted as in mock-infected cells (Figure 1). The reduced ability
of F170S HPIV1 to inhibit the induction of an antiviral state also
was reflected in the reduced plaque size of VSV-GFP on cells
infected with F170S HPIV1 versus cells infected with WT HIV1,
and the reduced expression of GFP (Figure S1).
Stat1 and Stat2 phosphorylation
Aiming to identify at what step IFN signaling was inhibited by
WT but not F170S HPIV1, we analyzed phosphorylation and
accumulation of Stat1 and Stat2. We infected Vero cells with
either virus for 48 h, mock-treated or treated the cells with
1000 IU/ml of the indicated IFN for 30 min, and subjected cell
lysates to Western blot analysis for total and phosphorylated (p)
Stat1 and Stat2 (Figure 2). This showed that, following IFN-a or
IFN-b treatment, total Stat1 accumulation was unchanged and
Stat1 phosphorylation at Tyr701 was reduced in both WT
HPIV1- and F170S HPIV1-infected cells (Figure 2). Unexpected-
ly, there was little difference between the WT and F170S viruses:
phosphorylation of Stat1 was only marginally increased for F170S.
This lack of difference between the WT and F170S viruses was
confirmed by examining multiple time points following IFN-b
treatment (Figure S2). Thus, the increase in IFN-a/b signaling
observed with F170S HPIV1 did not appear to be due to a loss
of the ability to inhibit Stat1 phosphorylation. Interestingly,
these results also indicate that the induction of a potent antiviral
state is possible (in F170S-infected cells) despite limited Stat1
phosphorylation.
WT or F170S HPIV1 infection also did not result in Stat2
degradation, in contrast to what is seen in HPIV2-infected cells
(Figure 2A) [44,45]. Phosphorylation of Stat2 in response to
stimulation with IFN-a or IFN-b was slightly reduced for F170S
HPIV1 and somewhat more for WT HPIV1. Again, this
difference seemed too small to explain the dramatic increase in
IFN-a/b signaling observed with F170S HPIV1. As expected,
treatment with IFN-c did not induce Stat2 phosphorylation, since
this is not involved in this signaling pathway.
Interestingly, following longer exposure of the Western blots
shown in Figure 2A, a small amount of phosphorylated Stat1
(pStat1) was detected in untreated WT HPIV1-infected cells but
not in F170S-infected cells (Figure 2B). One interpretation is that
there is a low level of Stat1 phosphorylation/dephosphorylation
even in the absence of in IFN-a/b (since Vero cells cannot
produce IFN-a/b) that is detectable because WT HPIV1 inhibits
dephosphorylation of this low background activity.
In summary, our findings indicate that HPIV1 infection did not
lead to Stat1/2 degradation and that phosphorylation of Stat1 and
Stat2 was reduced in WT HPIV1- and F170S HPIV1-infected
cells following stimulation with IFN-a and IFN-b. However, the
extent of Stat phosphorylation did not differ between WT and
F170S HPIV1 to an extent that would explain the marked
difference in IFN signaling between WT and F170S HPIV1.
Translocation of Stat1 and Stat2 to the nucleus
Since no significant differences were observed with regard to
Stat1 or Stat2 phosphorylation or stability between WT and
F170S HPIV1-infected cells, we next examined translocation of
Stat1 and Stat2 to the nucleus by confocal microscopy. Vero cells
were infected with WT or F170S HPIV1 at an MOI of 5 and,
48 h post-infection, were either mock-treated or treated with of
Figure 1. Signaling in WT or F170S HPIV1-infected Vero cells following treatment with IFN-a,- b,o r- c, assayed by VSV-GFP plaque
formation. Vero cells were mock-infected or infected with WT or F170S HPIV1 at an MOI of 5 TCID50/cell. After 48 h, cells were mock-treated or
treated with 100 or 1000 IU/ml of the indicated IFN for 24 h. Subsequently, cells were infected with GFP-expressing VSV, and VSV plaques were
enumerated 48 h later. Inhibition of VSV plaque formation is an indication of IFN signaling to create an antiviral state. The relative plaque numbers
are shown, as percent of the number of plaques that formed in non-IFN-treated wells. WT and F170S HPIV1-infected cells stimulated with 100 or
1000 IU of any of the three IFNs differed significantly in their ability to restrict VSV plaque formation (P values for two-tailed T-tests are indicated).
doi:10.1371/journal.pone.0028382.g001
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for the HPIV1 F and HN glycoproteins, to identify infected cells,
and for Stat1 (Figure 3) or Stat2 (Figure 4). As expected, IFN-b
treatment of mock-infected cells led to Stat1 translocation into the
nucleus in the majority of treated cells (Figure 3). Similar results
were observed following IFN-b treatment of F170S HPIV1-
infected cells, showing that the F170S mutant virus was unable to
inhibit translocation of Stat1 into the nucleus. In contrast, IFN-b
treatment of WT HPIV1-infected cells was largely unable to
induce Stat1 translocation to the nucleus, showing that WT
HPIV1 effectively inhibited this step. While only 2% of WT
HPIV1-infected cells stained positive for nuclear Stat1, 82% of the
F170S HPIV1-infected cells stained positive for nuclear Stat1. For
example, in the ‘‘WT+IFN’’ panel in Figure 3, Stat1 accumulated
in the nuclei of three uninfected cells (right side) but not in any of
the infected cells. Similarly, translocation of Stat2 to the nucleus in
response to IFN-b was effectively inhibited by WT HPIV1 but not
by F170S HPIV1 (Figure 4). While only 2% of WT HPIV1-
infected cells stained positive for nuclear Stat2 following IFNb
treatment, 100% of the F170S-infected cells were positive for
nuclear Stat2 (Figure 4). For example, Stat2 accumulated in the
nuclei of two cells at the left of the ‘‘WT+IFN’’ panel in Figure 4,
but these did not stain with the anti-HPIV1 antibodies and thus
were uninfected.
Co-immunoprecipitation of Stat1 and C9 protein
Since Stat1 and Stat2 were retained in the cytoplasm during
infection with WT HPIV1 but not F170S HPIV1, we investigated
whether retention might be due to physical interaction with the C
proteins, as has been reported for SeV C proteins, and whether the
C proteins interacted with both phosphorylated and unpho-
sphorylated Stat proteins. Co-immunoprecipitation studies were
performed using 293 T cells transfected with pcDNA3.1 plasmids
expressing either myc-tagged C9
WT or C9
F170S protein, or
untagged CAT protein as a negative control (Figure 5). This
showed that, indeed, the C9
WT-myc protein was able to co-
immunoprecipitate both unphosphorylated and phosphorylated
endogenous Stat1 (Figure 5, right panel). In contrast, the C9
F170S-
Figure 2. Western blot of total and phosphorylated Stat1 and Stat2 in WT or F170S HPIV1-infected Vero cells following treatment
with IFN-a,- b,o r- c. Vero cells were mock-infected or infected with WT HPIV1, F170S HPIV1, or HPIV2 at an MOI of 5 TCID50/cell. After 48 h, cells
were mock-treated or treated for 30 min with 1000 IU/ml of the indicated IFN. A) Western blots were probed for total or phosphorylated (p)Stat1 and
Stat2, as well as for the HPIV1 C protein and HPIV2 P protein. Alpha-tubulin was used as loading control. B) Extended exposure (over night) of the top
panel in Figure 2A [‘‘pStat1 (Tyr701)’’], showing that a low level of pStat1 is detected in cells infected with WT HPIV1 in the absence of IFN treatment.
doi:10.1371/journal.pone.0028382.g002
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Stat1 (Figure 5, right panel). We note that some co-immunopre-
cipiation of Stat1 was detected in untreated C9
WT-myc transfected
cells (fourth lane from the right), and that the amount of Stat1 co-
precipitation was increased in IFN stimulated cells. Interestingly,
the pStat1/Stat1 ratio was noticably higher in the precipitates
(Figure 5, right panel) than in the lysates (left panel). This suggests
that C9
WT proteins might bind pStat1 more efficiently than Stat1,
although this has not been investigated further.
We also note that the level of Stat1 phosphorylation in the total
lysates was not decreased in response to transfection with plasmid
expressing either C9
WT or C9
F170S (Figure 5), We attribute this to
the low transfection efficiency such that most cells did not express
C9 protein and thus phosphorylation of most of the Stat1 in the
culture would not be affected (not shown). In contrast, infection
with WT or F170S HPIV1 was very efficient and resulted in a
decrease in Stat1 phosphorylation that was evident in the total
lysate (Figure 2). We also attempted to co-immunoprecipitate
Stat2 with tagged C proteins but were unable to detect binding of
C9
WT or C9
F170S to Stat2 (data not shown).
Co-localization of Stat1 and HPIV1 C proteins
We next examined the distribution of the HPIV1 C proteins
and Stat1 in infected Vero cells using confocal microscopy. Vero
cells were mock-infected or infe c t e dw i t hW To rF 1 7 0 SH P I V 1 .
Forty-eight h later, the cells were mock-treated or treated with
1000 IU/ml of IFN-b, and were fixed 60 min post-treatment
and stained for HPIV1 C proteins (red) and endogenous Stat1
(green). Please note that the antiserum used to detect C proteins
produces some background staining (cytosolic in mock-treated
cells and nuclear in IFN treated cells [Figures 6 and 7, upper
two rows]). In uninfected, untreated Vero cells, Stat1 was
Figure 3. Intracellular localization of Stat1 in WT or F170S HPIV1-infected Vero cells following IFN treatment. Vero cells were mock-
infected or infected with WT or F170S HPIV1 at an MOI of 1 TCID50/cell, and 48 h later were mock-treated (-IFN) or treated (+IFN) with 1000 IU/ml of
IFN-b for 1 h. Cells were fixed, permeabilized, immunostained with antibodies for HPIV1 surface proteins (green) and Stat1 (red), stained with DAPI to
visualize nuclei (blue), and analyzed by confocal microscopy. Representative fields are shown. Overall, 2% of the WT HPIV1-infected cells and 82% of
the F170S HPIV1-infected cells showed nuclear Stat1 following IFN-b treatment.
doi:10.1371/journal.pone.0028382.g003
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pattern (Figure 6). Upon IFN-b treatment, the Stat1 signal
disappeared from the cytoplasm and concentrated in the
nucleus. In cells infected with WT HPIV1 without subsequent
IFN treatment, we observed that Stat1 was not distributed
evenly, and instead accumulated around the nucleus in coarse
perinuclear granules (Figure 6). In addition, in some infected
cells a modest Stat1 accumulation signal was observed along the
plasma membrane. In F170S-infected cells without subsequent
IFN treatment, perinuclear Stat1 accumulation was also
observed but formation of coarse granules was less distinct,
and more of the Stat1 signal was evenly distributed throughout
the cytoplasm. Following IFN treatment, the co-localization of
Stat1 and C proteins in coarse perinuclear granules persisted in
WT HPIV1-infected cells. In contrast, this co-localization
disappeared completely in F170S HPIV1-infected cells and a
strong Stat1 signal became visible in the nucleus (Figure 6).
Although some of the coarse perinuclear granules in F170S-
infected cells remained positive for C protein, they did not stain
for Stat1, indicating that F170S C proteins were unable to
retain Stat1 in these perinuclear granules and permitted
translocation of Stat1 to the nucleus.
The perinuclear aggregates containing the C proteins and Stat1
that were observed in Figure 6 were less evident in Figure 3. This
is because the photomicrographs in Figure 3 were taken at a
higher z-plane (cross-section), largely above the intracellular
location of the aggregates. With the use of a lower z-plane in
Figure 6, the aggregates were readily and reproducibly detected.
In order to visualize the three-dimensional distribution of the Stat1
and C signals in Figure 6, at least ten 0.17 mm cross-sections of
infected cells (z-stacks) were acquired and a 3D reconstruction of
the cells was performed (Videos S1, S2, S3, S4).
Figure 4. Intracellular localization of Stat2 in WT or F170S HPIV1-infected Vero cells following IFN treatment. Cells were infected and
analyzed as described in the legend to Figure 3 except that the antibodies against Stat1 were replaced with antibodies against Stat2 (red).
Representative fields are shown. Overall, 2% of the WT HPIV1-infected cells and 100% of the F170S HPIV1-infected cells showed nuclear Stat1
following IFN-b treatment.
doi:10.1371/journal.pone.0028382.g004
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Stat2, with M6PR
Aiming to identify the nature of these perinuclear granules in
which Stat1 and C proteins co-localized, we stained infected cells
with antibodies for a number of organelle-specific markers in
addition to the C proteins and Stats. Whereas staining for
endoplasmic reticulum (anti-protein disulfide isomerase [PDI]) or
mitochondria (mitochondrial 60 K protein) yielded no overlapping
signal (see Figure S3), staining using the late endosomal marker
M6PR showed a high degree of co-localization with the HPIV1 C
proteins (Figure 7 and Videos S5, S6, S7, S8) and Stat1 (Figure 8
and Videos S9, S10, S11, S12), but not Stat2 (Figure 9 and Videos
S13, S14, S15, S16). These findings suggest that the HPIV1 C
proteins associate with Stat1 on (or within) M6PR-positive vesicles,
i.e., on or in late endosomes or intermediate vesicles from the
trans-Golgi network. Specifically, the C proteins of both WT and
F170S HPIV1 co-localized with M6PR both before and after
stimulation with IFN-b. In the case of WT HPIV1, Stat1 also co-
localized with M6PR both before and after stimulation. In the case
of F170S HPIV1, Stat1 co-localized with M6PR before IFN-b
stimulation, whereas afterwards it translocated to the nucleus.
Stat2 appeared to be diffusely distributed in the cytoplasm of cells
infected with either WT or F170S HPIV1, in contrast to the
aggregated state of Stat1. Interestingly, following treatment of WT
HPIV1-infected cells with IFN-b, Stat2 also appeared to aggregate
in a perinuclear location (Figure 9). However, these aggregates did
not form the dense granules that were often seen with Stat1, and
these aggregates had less overlap with M6PR (Figure 9). In cells
infected with F170S HPIV1, these aggregates were not observed
following IFN-b treatment, and Stat2 accumulated in the nucleus,
consistent with previous results. The Videos S1, S2, S3, S4, S5, S6,
S7, S8, S9, S10, S11, S12, S13, S14, S15, S16 show the
perinuclear granules and the co-localization or lack of co-
localization in greater detail.
Discussion
Inhibition of type 1 IFN induction, IFN signaling, and the
establishment of an antiviral state are pivotal for efficient
replication of HPIV1 and many other viruses [46]. We have
previously shown that WT HPIV1 is able to suppress IFN-b
induction and signaling, while F170S HPIV1 is unable to do so
[25]. As a consequence, replication of F170S HPIV1 is restricted
more than 100-fold in the respiratory tract of non-human primates
[47]. In the present study, we took a closer look at the differences
in IFN signaling between WT and F170S HPIV1, aiming to define
at what step the virus-host interactions differ between these
viruses.
We used African green monkey Vero cells for all of our assays
except for the co-immunoprecipitation study, where 293 T cells
were used because of their high transfection and protein
expression efficiency. Vero cells are unable to express type 1 IFNs
but are fully able to respond to exogenous IFN. Thus, one can
evaluate IFN signaling in a controlled fashion by adding
exogenous IFN without the confounding effects of endogenously
produced IFN. This is particularly important because WT HPIV1
and F170S HPIV1 differ greatly in their ability to block IFN-b
induction [25], which would complicate the distinction between
effects on induction versus signaling. Vero cells also represent a
susceptible host for HPIV1 infection. We also performed every
experiment except the co-immunoprecipitation experiment in the
context of viral infection rather than cDNA expression, which
would provide an authentic environment for evaluating protein
function and distribution. In Vero cells, infection with WT HPIV1
but not F170S HPIV1 inhibited the induction of an antiviral state,
an indication of the extent of signaling following the addition of
exogenous IFN-a, IFN-b, or IFN-c. The level of restriction of
VSV-GFP following IFN treatment was similar in uninfected
versus F170S HPIV1-infected cells, indicating that this single point
mutation essentially ablated the ability of the virus to inhibit
signaling.
Although WT HPIV1 and WT SeV C proteins have previously
been shown to block type 1 IFN signaling, most of the available
information was for SeV, and it remained controversial where this
block occurs (Introduction) [6,26,48]. Here, we did not observe a
reduction in Stat1 or Stat2 accumulation in cells infected with WT
or F170S HPIV1, in contrast to what is seen with Rubulavirus
infection [45,49,50] (also see Figure 2). This is in agreement with
previous reports on WT HPIV1 in human MRC5 cells [6]. For
WT SeV, the situation is less clear, since the loss of Stat1 was
observed in murine NIH 3T3 and BALB/c fibroblasts [35] but not
in human HeLa or MRC5 cells [6,51].
We also found that, in response to treatment with IFN-a,- b,
and -c, the accumulation of pStat1 and pStat2 was reduced in WT
and F170S HPIV1-infected cells compared to mock-infected cells.
Though WT HPIV1-infected cells showed marginally less
phosphorylation for Stat2 than F170S HPIV1-infected cells, we
were surprised to find that the F170S HPIV1 did not differ more
drastically from WT HPIV1 in this regard. Thus we concluded
that the inability of the F170S mutant to block signaling in
response to IFN-a,- b, and -c could not be explained at the level of
phosphorylation of Stat1 and Stat2.
Following overnight exposure of Western blots, a small amount
of pStat1 was detected in the absence of IFN treatment in WT
HPIV1-infected cells, but not in F170S HPIV1-infected cells. A
similar IFN-independent increase in pStat1 accumulation was
previously reported for WT SeV and HPIV3 [51,52,53,54]. WT
SeV infection or expression of WT SeV C protein from transfected
plasmid in HeLa cells also inhibited dephosphorylation of Stat1
[51]. Garcin et al. confirmed that neither Stat2, nor a functional
IFN receptor, nor Jak1 were required for the SeV-mediated
increase in pY701-Stat1 accumulation [55], supporting the idea
that the increase in pStat1 resulted from virus-mediated inhibition
Figure 5. Co-immunoprecipitation of WT HPIV1 C protein and
Stat1. 293 T cells were transfected with pcDNA3.1(+)p l a s m i d s
expressing myc-tagged C9
WT or C9
F170S protein, or untagged CAT as a
negative control. After 48 h, cells were mock-treated (IFN2) or treated
(IFN+) with 1000 IU/ml of IFN-b for 30 min. Cell lysates were subjected
to immunoprecipitation with anti-myc antibodies. Whole cell lysates
and precipitates were separated on SDS-PAGE gels and analyzed by
Western blot with antibodies against pStat1, Stat1, or the C protein, as
indicated at the left. The experiment was carried out three times with
comparable outcomes.
doi:10.1371/journal.pone.0028382.g005
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stemming from a background level of IFN-independent phos-
phorylation. Thus, our results suggest that HPIV1, like SeV, also
inhibits dephosphorylation of Stat1. Since this activity was lost in
F170S HPIV1-infected cells, it likely is a function of the HPIV1 C
protein itself. While these observations further illustrate the greater
Stat1 binding of WT C proteins versus F170S C proteins, this
small amount of pStat1 present in the absence of IFN treatment
likely does not contribute to inducing an antiviral state, since it is
complexed with the C proteins.
Using fluorescence microscopy, we detected marked differences
between WT and F170S HPIV1-infected Vero cells with regard to
Stat1 and Stat2 translocation to the nucleus. WT HPIV1-infected
cells remained negative for nuclear Stat1 and Stat2 following IFN-
b treatment, but F170S HPIV1-infected cells permitted translo-
cation of Stat1 and Stat2 to the nucleus. Our data for WT HPIV1
agree with results from Bousse et al. in MRC-5 cells [6], but F170S
HPIV1 was not examined by these authors. The finding that a
single amino acid substitution in C permits translocation strongly
suggests that for WT HPIV1 the C protein is responsible for the
observed block. We also found that WT C protein, but not the
F170S C protein, could be co-immunoprecipitated with Stat1, as
has been reported for SeV [35,53]. Furthermore, WT C protein
co-immunoprecipitated with both the phosphorylated and non-
phosphorylated forms of Stat1, while co-immunoprecipitation with
Stat2 was not detected. Additionally, the ratio of pStat1 to Stat1
was noticeably higher in the precipitates than in the lysates,
suggesting that pStat1 was preferably bound by C9 protein. Such
preferential binding of the phosphorylated form of Stat1 would be
of interest, because it suggests that the C proteins preferentially
target the active form of Stat 1. This also raises the possibility that
the C proteins might bind to pStat1 contained in complexes such
as with Stat2 and destabilize these complexes. However, further
investigation using methods more suitable to measure binding
Figure 6. Co-localization of Stat1 and HPIV1 C proteins in Vero cells. Vero cells were mock-infected or infected with WT or F170S HPIV1 at an
MOI of 1 TCID50/cell. After 48 h, cells were mock-treated (2IFN) or treated with 1000 IU/ml of IFN-b (+IFN) for 30 min. Cells were subsequently fixed,
permeabilized, and stained for HPIV1 C proteins (red) and endogenous Stat1 protein (green). Z-stacks of Figure 6 are shown in the Videos S1, S2, S3,
S4.
doi:10.1371/journal.pone.0028382.g006
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association with pStat1.
Unexpectedly, we found that most of the Stat1 and C proteins
in WT and F170S HPIV1-infected cells co-localized in fairly large
perinuclear granules in the cytoplasm. While these complexes were
observed with both viruses, the signal was somewhat less granular
and dense with the F170S virus. Furthermore, for both viruses,
these complexes largely co-localized with M6PR, which is a widely
used marker for late endosomes. We believe this is the first report
of the association of Respirovirus C proteins with large aggregates
associated with the late endosome. Takeuchi et al. noted high
molecular weight C protein:Stat1 complexes in SeV-infected cells
based on size exclusion chromatography [53], but these complexes
were not directly visualized in infected cells. In contrast to the
present report, the SeV C proteins have generally been described
as being associated with the plasma membrane. Marq et al.
previously proposed that the SeV C proteins might be anchored to
the plasma membrane by an amphipathic helix at the N-terminus
of the C protein [56]. Also, Sakaguchi et al. reported co-
localization of C proteins with Alix/AIP1 along the plasma
membrane [57], suggesting that C proteins might recruit Alix to
the plasma membrane to facilitate virus budding [22]. However,
the significance of Alix for SeV budding is still controversial [24].
For HPIV1, most of the C protein and Stat1 protein in Vero cells
infected with either the WT or F170S mutant appeared to be
contained in these aggregates and not at the plasma membrane.
Stat2 was distributed more evenly throughout the cytosol and in
contrast to Stat1 did not seem to co-localize with M6PR. We note
that two of the phenotypes that we do not detect, but which are
described for SeV, namely Stat1 loss [36] and pronounced
localization of either C proteins or Stat1 [56] to the plasma
membrane, have both been ascribed to the N-terminal 23 amino
acids of the SeV C9 protein, a region that is poorly conserved
between HPIV1 and SeV.
The structure of the aggregates containing the C proteins, Stat1,
and M6PR remains to be defined. Since the HPIV1 C proteins
appear to lack a sequence for translocation across membrane, and
since Stat1 quickly relocated to the nucleus in F170S HPIV1-
Figure 7. Co-localization of C proteins and mannose6-phosphate receptor in Vero cells. Vero cells were treated as described for Figure 6.
Cells were stained for HPIV1 C proteins (red) and M6PR (green). Z-stacks of Figure 7 are shown in the Videos S5, S6, S7, S8.
doi:10.1371/journal.pone.0028382.g007
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protein:Stat1 complexes are located on the cytoplasmic face of late
endosomes, rather than within the vesicles. Our microscopy data
also suggests that the C protein might change the distribution of
the late endosome. In non-infected cells, the late endosome looks
polarized and sits like a cap on the nucleus. In contrast, in infected
cells, distinct vesicles are frequently distributed all around the
nucleus.
Stat2 did not appear to co-localize in these perinuclear
aggregates, based on several observations. First, in the absence
of IFN-b treatment, Stat2 appeared to be diffusely distributed in
WT or F170S HPIV1-infected cells, in contrast to the Stat1
aggregates that clustered in the perinuclear space. Second, the
Stat2-containing aggregates were not as well defined and not as
dense as Stat1 aggregates. Third, these granules did not co-localize
for the most part with M6PR. The finding that the Stat1-
containing granules do not appear to contain Stat2 suggests that
the C proteins bind predominantly to monomeric Stat1 rather
than to the ISGF3 complex (Stat1:Stat2:IRF9). This suggestion is
supported by the finding that Stat2 did not co-immunoprecipitate
with C proteins, as would have been observed if the C proteins
bound to ISGF3 complexes.
We previously tried to identify C protein binding partners using
yeast-two-hybrid assays or immunoprecipitation, size-separation
and mass-spectroscopy (unpublished data), but neither method
identified Stat1 as a C protein binding partner. Only when the C9
protein (the largest form of the C proteins) was over-expressed in
293 T cells and the washing conditions for the immunoprecipi-
tation were adjusted, could we co-immunoprecipitate Stat1 (and
pStat1) protein with the WT HPIV1 C9 protein. Based on these
findings, we suggest that the HPIV1 C proteins bind Stat1 (and
pStat1) with only modest affinity to create an equilibrium that
permits the binding partners to be exchanged and passed on
frequently, and that a certain fraction of Stat1 proteins remains
unbound at any time. Our studies suggest that the F170S C
protein has an even lower affinity to Stat1 than does the WT C
protein since it did not detectably immunopreciptate Stat1 and did
not prevent Stat1 from entering the nucleus, thus permitting the
Figure 8. Co-localization of Stat1 and mannose6-phosphate receptor in Vero cells. Vero cells were treated as described for Figure 6. Cells
were stained for Stat1 (red) and M6PR (green). Z-stacks of Figure 8 are shown in the Videos S9, S10, S11, S12.
doi:10.1371/journal.pone.0028382.g008
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proteins towards Stat1, as compared to F170S C proteins, also was
suggested by the detection of residual pStat1 in WT HPIV1-
infected cells in the absence of IFN stimulation, whereas no pStat1
was detected in F170S HPIV1-infected cells in the absence of IFN
stimulation, as already noted.
Depending on the particular virus, members of Paramyxovir-
inae may express both V and C (e.g., SeV; members of genus
Morbillivirus [e.g. measles virus]; and members of Henipavirus
[i.e., Nipah and Hendra viruses]), or only V (members of genus
Rubulavirus [e.g. HPIV2] and Avulavirus [e.g., Newcastle disease
virus]), or only C (HPIV1 and possibly HPIV3, as noted in the
Introduction). Even though the C and V proteins are completely
distinct, they can have similar effects in blocking host cell innate
responses. However, the mechanisms involved can vary consider-
ably between the two proteins and between different viruses,
including the mechanisms for blocking signaling from the IFN-a/b
receptor. As already noted, for SeV, IFN signaling appears to be
blocked by the C proteins but not the V protein, involving
inhibition of Stat phosphorylation and possibly degradation of
Stat1 (Introduction). For the Rubulaviruses, the V protein was
shown to promote degradation of Stat1 (parainfluenza virus 5 [49]
and mumps virus [58]) or Stat2 (HPIV2 [50], also see Figure 2).
For the Avulavirus Newcastle disease virus, the V protein inhibits
IFN signaling by targeting Stat1 for degradation [59]. The V
proteins but not the C proteins of measles virus inhibit IFN
signaling by inhibiting Stat1 and Stat2 phosphorylation, but
degradation of Stat1 or Stat2 was not observed [60,61]. For
Hendra and Nipah viruses, the V proteins inhibit signaling by
binding to both Stat1 and Stat2, inhibiting their phosphorylation
and creating cytoplasmic aggregates [62,63]. Whether these Stat1
and Stat2 aggregates with the Henipavirus V proteins have any
similarity to the aggregates between Stat1 and the HIPV1 C
proteins reported in the present study is not known. Thus, there is
little consistency with regard to the specific mechanisms associated
with C or V or within most genera.
In summary, these studies showed that both the WT HPIV1
and the F170S mutant retain the ability to inhibit phosphorylation
Figure 9. Co-localization of Stat2 and mannose6-phosphate receptor in Vero cells. Vero cells were treated as described for Figure 6. Cells
were stained with for Stat2 (red) and M6PR (green). Z-stacks of Figure 9 are shown in the Videos S13, S14, S15, S16.
doi:10.1371/journal.pone.0028382.g009
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F170S mutant to block IFN signaling is not due to the loss of this
ability. We found that the WT C proteins bind to Stat1 and pStat1
and sequester them in aggregates that co-localize with the late
endosomal marker M6PR and are little affected by IFN treatment.
This sequestration appears to be the mechanism by which the
HPIV1 C proteins block signaling. Stat2 did not co-localize with
M6PR or co-precipitate with C proteins, indicating that it was not
contained in these aggregates. While the F170S C proteins
retained the ability to aggregate Stat1 in perinuclear granules, they
were unable to prevent nuclear translocation following IFN
treatment. Co-immunopreciptation experiments indicated that
this reflected lower-affinity binding due to the mutation. These
results describe the mode of action of one of the major attenuating
mutations present in a live attenuated HPIV1 vaccine candidate
presently being evaluated in clinical trials (ClinicalTrials.gov ID
NCT00641017).
Materials and Methods
Cells, Viruses and Plasmids
Vero cells (ATCC: CCL-81), LLC-MK2 cells (ATCC: CCL-7)
and 293 T cells (ATCC: CRL-11268) were grown in OptiMEM
(Gibco), supplemented with 10% fetal bovine serum (FBS).
Infections with HPIV1 viruses were carried out using OptiMEM
containing 1.2% Trypsin (Gibco) but no FBS. The recombinant
F170S HPIV1 mutant was constructed in previous work to contain
a phenylalanine-to-serine substitution at position 170 of the C
protein but otherwise was confirmed by sequence analysis of the
complete genome to be identical to its recombinant WT HPIV1
parent [26]. These viruses were grown in LLC-MK2 cells and
purified on sucrose gradients as previously described to remove
cytokines and other molecules derived from the infected cell [26].
VSV-GFP, a recombinant vesicular stomatitis virus expressing the
green fluorescent protein from the first position in the genome, was
grown in Vero cells [64]. The open reading frames of WT and
F170S C9 protein (i.e., the longest version of the C protein) were
PCR amplified and PCR products were cloned into pcDNA3.1(+)
vectors. A pcDNA3.1(+) vector expressing untagged chloram-
phenicol acetyltransferase (CAT) protein was used as a negative
control.
VSV-GFP signaling assays
Vero cells were seeded into 6-well plates and two days later were
infected with sucrose-purified WT or F170S HPIV1 at a
multiplicity of infection (MOI) of 5 tissue culture infectious dose
50% (TCID50) per cell. 48 h later, cells were stimulated with 0,
100 or 1000 IU of IFN-a2a (Intron A, Schering), IFN-b1a
(Avonex, Biogen) or IFN-c (R&D, 285-IF/CF) for an additional
24 h. Cells were subsequently infected with 100 plaque-forming
units of VSV-GFP per well and covered with overlay medium
(OptiMEM+0.8% methylcellulose). Plaques were read 48 h later.
Western Blots
Vero cells were seeded in 6-well plates and infected with
sucrose-purified viruses at an MOI of 5. After 48 h of infection,
cells were stimulated with 0 or 1000 IU of IFN-b1 for 30 min and
subsequently lysed in 150 ml RIPA buffer (20 mM Tris-HCl,
100 mM NaCl, 1 mM EDTA, 1%NP-40, 1% Sodium deoxicho-
late, 0.1% SDS, pH 8.0 supplemented with protease and
phosphatase inhibitors) per well. 10 ml of the lysates were
separated on SDS-PAGE gels, blotted onto PVDF membranes,
and probed with antibodies to phosphorylated (p)Stat1 (Y701)
(Cell Signaling, #9171: 1:1000), pStat2 (Y690) (Cell Signaling,
#4441: 1:500), Stat1 (Cell Signaling, #9172, 1:1000), Stat2 (Santa
Cruz, sc-464, 1:300), PIV1 C proteins (Y2-35, polyclonal rabbit
antiserum raised against the peptide TITTKTEQSQRRPK,
which represents amino acids 79 to 91 in the C9 protein and
thus reacts with all forms of C proteins, used at a dilution of
1:2000), PIV2 P/V protein (mouse monoclonal, 85A, kind gift of
Dr. Nishio [65] 1:2000), and a-tubulin (Sigma, TG199, 1:10000).
Secondary antibodies from KPL (goat-anti-mouse-HRP, 074-1806
and goat-anti-rabbit-HRP, 074-1506) were used at concentrations
of 100 ng/ml and bands were detected by chemiluminescence
(Western Pico Detection Kit, Invitrogen) on Kodak Biomax MR
films.
Confocal Microscopy
Vero cells were seeded on cover slips in 24-well plates and were
infected two days later with sucrose-purified viruses at an MOI of
1. After 48 h of infection, cells were stimulated with 1000 IU/ml
of IFN-b1 for 1 h. Cells were subsequently washed with PBS, fixed
with 2% paraformaldehyde in PBS for 10 min, permeabilized with
0.3% Triton X-100 in PBS for 10 min and then incubated in
blocking buffer for at least 10 min (0.75% BSA+0.25% Gelatin in
PBS). Cells were incubated with primary and secondary antibodies
for 1 h each and washed with PBS three times. Cover slips were
mounted on microscopy slides with DAPI-containing ProLong
Gold reagent (Invitrogen). The following primary antibodies were
used: anti-PIV1-C (rabbit, Y2-35, as above, 1:1200), anti-PIV1 F/
HN (1:1 mixture of two mouse monoclonal antibodies against F
and HN (F: 7.1; HN: 8.2.2.A [66]); 1:1200), anti-Stat1 (rabbit,
Santa-Cruz, sc-346, 1:150), anti-Stat1 (mouse; Santa-Cruz; sc-464;
1:600) and anti-Stat2 (rabbit; Santa-Cruz, sc-476,1:150), and anti-
cation independent mannose 6-phosphate receptor (M6PR,
mouse, abcam, ab8093, 1:400). The secondary antibodies were
FITC-anti-mouse (Rockland, 810–1202, 3 mg/ml) and Alexa594
anti-rabbit (Invitrogen, A21207, 13 mg/ml). All antibodies were
applied in 300 ml blocking buffer. Microscopy images were
generated on a Leica Microsystems SP5 confocal microscope
using a 636oil immersion objective. For Figures 6 through 9 and
the corresponding supplementary files an additional 36zoom was
applied to emphasize the intracellular structures. For quantifica-
tion of Stat translocation to the nucleus, an investigator blinded to
the treatment conditions examined 50 infected cells per read-out.
Immunoprecipitation
Although all of the other experiments described above were
carried out using Vero cells, these cells were difficult to transfect
and did not express transfected plasmids efficiently. For this
reason, we turned to 293 T cells for immunoprecipitation
experiments. 293 T cells are 293 cells stably expressing the
SV40 large T antigen, and plasmids containing the SV40 origin of
replication are efficiently expressed. 293 T cells were seeded in 6-
well plates and 2 days later they were transfected, using
Lipofectamine 2000 (Invitrogen), with 5 mg of pcDNA3.1(+) per
well, expressing either the WT or F170S C protein with a
carboxyterminal myc-tag, or expressing untagged CAT protein
(negative control). Cells were lysed in 600 ml lysis buffer
(PBS+0.1% NP-40), 500 ml of which were incubated over night
in a shaker with 20 ml of anti-C-myc agarose (Sigma, A7470). The
slurry was washed twice with lysis buffer and proteins were eluted
using 100 ml of 1xLDS Sample Buffer (Invitrogen, NP0008).
Supporting Information
Figure S1 Control experiments for the VSV-GFP assay
used to quantify the IFN-induced antiviral state. A) VSV-
HPIV1 C Proteins Retain Stat1 at Late Endosome
PLoS ONE | www.plosone.org 12 February 2012 | Volume 7 | Issue 2 | e28382GFP plaque morphology. Vero cells were infected with sucrose
gradient-purified WT or F170S HPIV1 at a multiplicity of
infection (MOI) of 5 TCID50 per cell. 48 h later, cells were
stimulated with 0, 100 or 1000 IU IFN-b1a (Avonex, Biogen) for
an additional 24 h. Cells were subsequently infected with about
100 plaque-forming units of VSV-GFP per well and covered with
overlay medium (OptiMEM+0.8% methylcellulose). Plaques were
visualized 48 h later using a Molecular Dynamics Phosphorima-
ger. B) GFP expression. Vero cells were seeded and infected
similarly but the stimulation with 0, 100 or 1000 IU IFN-b1a was
only 30 min. Cells were subsequently washed three times with PBS
and infected with about 100 plaque-forming units of VSV-GFP
per well. Afterwards OptiMEM without any supplements was
added. Cells were lysed after 24 h and lysates were probed for
GFP (abcam, ab290, 1:500) and a-tubulin (Sigma, TG199,
1:10000).
(TIF)
Figure S2 Control experiment to show that the level of
Stat1 phosphorylation following IFN stimulation is
similar over time in WT HPIV1-infected versus F170S
HPIV1-infected cells. Vero cells were infected with WT
HPIV1 or F170S HPIV1 or mock-infected at an MOI of 5. After
48 h of infection, cells were stimulated with 1000 IU/ml of IFN-
b1 for multiple intervals. Cells were lysed in RIPA Buffer and
10 ml of the lysates were separated on SDS-PAGE gels, blotted
onto PVDF membranes, and probed with antibodies to phos-
phorylated (p)Stat1 (Y701) (Cell Signaling, #9171: 1:1000) and
Stat1 (Cell Signaling, #9172, 1:1000).
(TIF)
Figure S3 The HPIV1 C proteins co-localize with the
M6PR marker for late endosomes and not with markers
for mitochondria or the endoplasmic reticulum. Vero
cells were infected with WT HPIV1 at an MOI of 0.5. After 48 h
of infection, cells were stimulated with 1000 IU/ml of IFN-b1 for
1 h. Cells were subsequently washed with PBS, fixed with 2%
paraformaldehyde in PBS for 10 min, permeabilized with 0.3%
Triton X-100 in PBS for 10 min and then incubated in blocking
buffer for at least 10 min (0.75% BSA+0.25% Gelatin in PBS).
Cells were incubated with primary and secondary antibodies for
1 h each and washed with PBS three times. Cover slips were
mounted on microscopy slides with DAPI-containing ProLong
Gold reagent (Invitrogen). Primary antibodies were mouse-derived
antibodies from abcam: ab3298 (mitochondria marker 1:150),
ab8093 (M6PR, late endosome marker, 1:400), and ab2792 (anti-
PDI, ER marker, 1:200).
(TIF)
Video S1 Supplemental video files for Figure 6 (Stat1
and C proteins). Vero cells were infected with WT HPIV1 for
48 h, mock-stimulated with medium containing neither FCS nor
IFN-b for 1 h and subsequently fixed, permeabilized and stained
for nucleus (DAPI, blue), Stat1 (green) and C proteins (red).
Images of cross-sections (z-stacks) of 0.17 mm thickness were
acquired on a Leica SP5 confocal microscope and 3D reconstruc-
tions were generated using Imaris software (Bitplane, Zurich,
Switzerland). The first of the two rotations of the 3D reconstruc-
tion shows all three channels as indicated above, the second
rotation shows the blue channel (DAPI, nucleus) and the ‘‘co-
localization channel’’ (yellow, calculated from the co-localizing
signals of the red and the green channels). Note that there is some
cell-to-cell variability in expression: for example, the cell that is
initially at the lower right expresses C proteins (red) but little Stat1
(green).
(MOV)
Video S2 Supplemental video file for Figure 6 (Stat1 and
C proteins). Vero cells were infected with WT HPIV1 for 48 h,
stimulated with medium containing no FCS but IFN-b (1000 IU/
ml) for 1 h and subsequently fixed, permeabilized and stained for
nucleus (DAPI, blue), Stat1 (green) and C proteins (red). Images of
cross-sections (z-stacks) of 0.17 mm thickness were acquired on a
Leica SP5 confocal microscope and 3D reconstructions were
generated using Imaris software (Bitplane, Zurich, Switzerland).
The first of the two rotations of the 3D reconstruction shows all
three channels as indicated above, the second rotation shows the
blue channel (DAPI, nucleus) and the ‘‘co-localization channel’’
(yellow, calculated from the co-localizing signals of the red and the
green channels).
(MOV)
Video S3 Supplemental video file for Figure 6 (Stat1 and
C proteins). Vero cells were infected with F170S HPIV1 for
48 h, mock-stimulated with medium containing neither FCS nor
IFN-b for 1 h and subsequently fixed, permeabilized and stained
for nucleus (DAPI, blue), Stat1 (green) and C proteins (red).
Images of cross-sections (z-stacks) of 0.17 mm thickness were
acquired on a Leica SP5 confocal microscope and 3D reconstruc-
tions were generated using Imaris software (Bitplane, Zurich,
Switzerland). The first of the two rotations of the 3D reconstruc-
tion shows all three channels as indicated above, the second
rotation shows the blue channel (DAPI, nucleus) and the ‘‘co-
localization channel’’ (yellow, calculated from the co-localizing
signals of the red and the green channels).
(MOV)
Video S4 Supplemental video file for Figure 6 (Stat1 and
C proteins). Vero cells were infected with F170S HPIV1 for
48 h, stimulated with medium containing no FCS but IFN-b
(1000 IU/ml) for 1 h and subsequently fixed, permeabilized and
stained for nucleus (DAPI, blue), Stat1 (green) and C proteins
(red). Images of cross-sections (z-stacks) of 0.17 mm thickness were
acquired on a Leica SP5 confocal microscope and 3D reconstruc-
tions were generated using Imaris software (Bitplane, Zurich,
Switzerland). For better visibility of the nuclear localization of
Stat1, the first of the two rotations of the 3D reconstruction shows
the Stat1 (green) and C proteins (red) channels but not the blue
channel (DAPI, nucleus). The second rotation shows the blue
channel (DAPI, nucleus) and the ‘‘co-localization channel’’
(yellow, calculated from the co-localizing signals of the red and
the green channels).
(MOV)
Video S5 Supplemental video file for Figure 7 (M6PR
and C proteins). Vero cells were infected with WT HPIV1 for
48 h, mock-stimulated with medium containing neither FCS nor
IFN-b for 1 h and subsequently fixed, permeabilized and stained
for nucleus (DAPI, blue), M6PR (green) and C proteins (red).
Images of cross-sections (z-stacks) of 0.17 mm thickness were
acquired on a Leica SP5 confocal microscope and 3D reconstruc-
tions were generated using Imaris software (Bitplane, Zurich,
Switzerland). The first of the two rotations of the 3D reconstruc-
tion shows all three channels as indicated above, the second
rotation shows the blue channel (DAPI, nucleus) and the ‘‘co-
localization channel’’ (yellow, calculated from the co-localizing
signals of the red and the green channels).
(MOV)
Video S6 Supplemental video file for Figure 7 (M6PR
and C proteins). Vero cells were infected with WT HPIV1 for
48 h, stimulated with medium containing no FCS but IFN-b
(1000 IU/ml) for 1 h and subsequently fixed, permeabilized and
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(red). Images of cross-sections (z-stacks) of 0.17 mm thickness were
acquired on a Leica SP5 confocal microscope and 3D reconstruc-
tions were generated using Imaris software (Bitplane, Zurich,
Switzerland). The first of the two rotations of the 3D reconstruc-
tion shows all three channels as indicated above, the second
rotation shows the blue channel (DAPI, nucleus) and the ‘‘co-
localization channel’’ (yellow, calculated from the co-localizing
signals of the red and the green channels).
(MOV)
Video S7 Supplemental video file for Figure 7 (M6PR
and C proteins). Vero cells were infected with F170S HPIV1
for 48 h, mock-stimulated with medium containing neither FCS
nor IFN-b for 1 h and subsequently fixed, permeabilized and
stained for nucleus (DAPI, blue), M6PR (green) and C proteins
(red). Images of cross-sections (z-stacks) of 0.17 mm thickness were
acquired on a Leica SP5 confocal microscope and 3D reconstruc-
tions were generated using Imaris software (Bitplane, Zurich,
Switzerland). The first of the two rotations of the 3D reconstruc-
tion shows all three channels as indicated above, the second
rotation shows the blue channel (DAPI, nucleus) and the ‘‘co-
localization channel’’ (yellow, calculated from the co-localizing
signals of the red and the green channels).
(MOV)
Video S8 Supplemental video file for Figure 7 (M6PR
and C proteins). Vero cells were infected with F170S HPIV1
for 48 h, stimulated with medium containing no FCS but IFN-b
(1000 IU/ml) for 1 h and subsequently fixed, permeabilized and
stained for nucleus (DAPI, blue), M6PR (green) and C proteins
(red). Images of cross-sections (z-stacks) of 0.17 mm thickness were
acquired on a Leica SP5 confocal microscope and 3D reconstruc-
tions were generated using Imaris software (Bitplane, Zurich,
Switzerland). The first of the two rotations of the 3D reconstruc-
tion shows all three channels as indicated above, the second
rotation shows the blue channel (DAPI, nucleus) and the ‘‘co-
localization channel’’ (yellow, calculated from the co-localizing
signals of the red and the green channels).
(MOV)
Video S9 Supplemental video file for Figure 8 (M6RP
and Stat1). Vero cells were infected with WT HPIV1 for 48 h,
mock-stimulated with medium containing neither FCS nor IFN-b
for 1 h and subsequently fixed, permeabilized and stained for
nucleus (DAPI, blue), M6PR (green) and Stat1 (red). Images of
cross-sections (z-stacks) of 0.17 mm thickness were acquired on a
Leica SP5 confocal microscope and 3D reconstructions were
generated using Imaris software (Bitplane, Zurich, Switzerland).
The first of the two rotations of the 3D reconstruction shows all
three channels as indicated above, the second rotation shows the
blue channel (DAPI, nucleus) and the ‘‘co-localization channel’’
(yellow, calculated from the co-localizing signals of the red and the
green channels).
(MOV)
Video S10 Supplemental video file for Figure 8 (M6RP
and Stat1). Vero cells were infected with WT HPIV1 for 48 h,
stimulated with medium containing no FCS but IFN-b (1000 IU/
ml) for 1 h and subsequently fixed, permeabilized and stained for
nucleus (DAPI, blue), M6PR (green) and Stat1 (red). Images of
cross-sections (z-stacks) of 0.17 mm thickness were acquired on a
Leica SP5 confocal microscope and 3D reconstructions were
generated using Imaris software (Bitplane, Zurich, Switzerland).
The first of the two rotations of the 3D reconstruction shows all
three channels as indicated above, the second rotation shows the
blue channel (DAPI, nucleus) and the ‘‘co-localization channel’’
(yellow, calculated from the co-localizing signals of the red and the
green channels).
(MOV)
Video S11 Supplemental video file for Figure 8 (M6RP
and Stat1). Vero cells were infected with F170S HPIV1 for 48 h,
mock-stimulated with medium containing neither FCS nor IFN-b
for 1 h and subsequently fixed, permeabilized and stained for
nucleus (DAPI, blue), M6PR (green) and Stat1 (red). Images of
cross-sections (z-stacks) of 0.17 mm thickness were acquired on a
Leica SP5 confocal microscope and 3D reconstructions were
generated using Imaris software (Bitplane, Zurich, Switzerland).
The first of the two rotations of the 3D reconstruction shows all
three channels as indicated above, the second rotation shows the
blue channel (DAPI, nucleus) and the ‘‘co-localization channel’’
(yellow, calculated from the co-localizing signals of the red and the
green channels).
(MOV)
Video S12 Supplemental video file for Figure 8 (M6RP
and Stat1). Vero cells were infected with F170S HPIV1 for
48 h, stimulated with medium containing no FCS but IFN-b
(1000 IU/ml) for 1 h and subsequently fixed, permeabilized and
stained for nucleus (DAPI, blue), M6PR (green) and Stat1 (red).
Images of cross-sections (z-stacks) of 0.17 mm thickness were
acquired on a Leica SP5 confocal microscope and 3D
reconstructions were generated using Imaris software (Bitplane,
Zurich, Switzerland). For better visibility of the nuclear
localization of Stat1, the first of the two rotations of the 3D
reconstruction shows the Stat1 (green) and C proteins (red)
channels but not the blue channel (DAPI, nucleus). The second
rotation shows the blue channel (DAPI, nucleus) and the ‘‘co-
localization channel’’ (yellow, calculated from the co-localizing
signals of the red and the green channels).
(MOV)
Video S13 Supplemental video file for Figure 9 (M6PR
and Stat2). Vero cells were infected with WT HPIV1 for 48 h,
mock-stimulated with medium containing neither FCS nor IFN-b
for 1 h and subsequently fixed, permeabilized and stained for
nucleus (DAPI, blue), M6PR (green) and Stat2 (red). Images of
cross-sections (z-stacks) of 0.17 mm thickness were acquired on a
Leica SP5 confocal microscope and 3D reconstructions were
generated using Imaris software (Bitplane, Zurich, Switzerland).
The first of the two rotations of the 3D reconstruction shows all
three channels as indicated above, the second rotation shows the
blue channel (DAPI, nucleus) and the ‘‘co-localization channel’’
(yellow, calculated from the co-localizing signals of the red and the
green channels).
(MOV)
Video S14 Supplemental video file for Figure 9 (M6PR
and Stat2). Vero cells were infected with WT HPIV1 for 48 h,
stimulated with medium containing no FCS but IFN-b (1000 IU/
ml) for 1 h and subsequently fixed, permeabilized and stained for
nucleus (DAPI, blue), M6PR (green) and Stat2 (red). Images of
cross-sections (z-stacks) of 0.17 mm thickness were acquired on a
Leica SP5 confocal microscope and 3D reconstructions were
generated using Imaris software (Bitplane, Zurich, Switzerland).
The first of the two rotations of the 3D reconstruction shows all
three channels as indicated above, the second rotation shows the
blue channel (DAPI, nucleus) and the ‘‘co-localization channel’’
(yellow, calculated from the co-localizing signals of the red and the
green channels).
(MOV)
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and Stat2). Vero cells were infected with F170S HPIV1 for 48 h,
mock-stimulated with medium containing neither FCS nor IFN-b
for 1 h and subsequently fixed, permeabilized and stained for
nucleus (DAPI, blue), M6PR (green) and Stat2 (red). Images of
cross-sections (z-stacks) of 0.17 mm thickness were acquired on a
Leica SP5 confocal microscope and 3D reconstructions were
generated using Imaris software (Bitplane, Zurich, Switzerland).
The first of the two rotations of the 3D reconstruction shows all
three channels as indicated above, the second rotation shows the
blue channel (DAPI, nucleus) and the ‘‘co-localization channel’’
(yellow, calculated from the co-localizing signals of the red and the
green channels).
(MOV)
Video S16 Supplemental video file for Figure 9 (M6PR
and Stat2). Vero cells were infected with F170S HPIV1 for 48 h,
stimulated with medium containing no FCS but IFN-b (1000 IU/
ml) for 1 h and subsequently fixed, permeabilized and stained for
nucleus (DAPI, blue), M6PR (green) and Stat2 (red). Images of
cross-sections (z-stacks) of 0.17 mm thickness were acquired on a
Leica SP5 confocal microscope and 3D reconstructions were
generated using Imaris software (Bitplane, Zurich, Switzerland).
For better visibility of the nuclear localization of Stat1, the first of
the two rotations of the 3D reconstruction shows the Stat1 (green)
and C proteins (red) channels but not the blue channel (DAPI,
nucleus). The second rotation shows the blue channel (DAPI,
nucleus) and the ‘‘co-localization channel’’ (yellow, calculated
from the co-localizing signals of the red and the green channels).
(MOV)
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